Skip to content

Study · Not a test of the peptide alone · 2026

2 results

The effect of GLP-1 receptor agonists on autophagy: insights gathered from research evaluating neurodegenerative disorders with these agents.

Sioufi MC, Heroiu I, Wong S, Le GH, Dri CE, Zheng YJ, Teopiz KM, Rhee TG, Lo HKY, Guillen-Burgos HF, McIntyre RS

Acta neuropsychiatrica13 Feb 2026Cited by 2 (Europe PMC)

PMID41684077 (opens in a new tab)PMCIDPMC13130272 (opens in a new tab)DOI10.1017/neu.2026.10060 (opens in a new tab)PepBankPUB-41684077
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

ObjectiveImpaired autophagy has been implicated in the pathophysiology of neurodegenerative disorders, such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Consistent and replicated evidence indicate that Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) exert treatment and preventative effects across disparate neurologic and mental disorders, potentially through mechanisms involving autophagy. This systematic review examined the effects of GLP-1RAs on autophagy in cell and animal models of AD and PD, as a proof of concept, to determine if these agents can be repurposed for the prevention and treatment of neurodegenerative and other mental disorders.MethodsA systematic search on PubMed, Web of Science, and OVID (Medline, Embase, and APA PsycInfo databases) was conducted from inception to June 17, 2025. Screening was performed independently by two reviewers (MCS and IH) using predefined inclusion and exclusion criteria. Subsequently, a quality assessment was conducted.ResultsThe search yielded 142 studies, of which 14 were included. Across studies, GLP-1RAs (e.g., liraglutide, semaglutide, and exendin-4) autophagy-specific markers, including beclin-1, LC3-II/LC3-I, ATG7, ATG3, and LAMP1, while normalising p62 levels.DiscussionIn addition to promoting neurogenesis, neuroplasticity, and reducing inflammation, GLP-1RAs appear to modulate molecular and cellular systems contributing to autophagy, potentially mediating their broad therapeutic effects. Collectively, these studies present promising findings of GLP-1RAs for neurodegenerative and mental disorders; however, further studies are required to establish their translatability to human populations.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01AnimalNot a test of Liraglutide aloneOther designMechanism

    Across cell and animal studies, pooled GLP-1 receptor agonists including liraglutide normalised p62 levels.

    In plain wordsIn cell and animal studies, pooled GLP-1 receptor agonists including liraglutide normalised p62 levels.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedp62 levels
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Across studies, GLP-1RAs (e.g., liraglutide, semaglutide, and exendin-4) autophagy-specific markers, including beclin-1, LC3-II/LC3-I, ATG7, ATG3, and LAMP1, while normalising p62 levels.
    3 context sentences
    Summary · context
    This systematic review examined the effects of GLP-1RAs on autophagy in cell and animal models of AD and PD, as a proof of concept, to determine if these agents can be repurposed for the prevention and treatment of neurodegenerative and other mental disorders.
    Summary · context
    A systematic search on PubMed, Web of Science, and OVID (Medline, Embase, and APA PsycInfo databases) was conducted from inception to June 17, 2025.
    Summary · context
    The search yielded 142 studies, of which 14 were included.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02AnimalNot a test of Semaglutide aloneOther designMechanism

    Across cell and animal studies, pooled GLP-1 receptor agonists including semaglutide normalised p62 levels.

    In plain wordsIn cell and animal studies, pooled GLP-1 receptor agonists including semaglutide normalised p62 levels.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedp62 levels
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Across studies, GLP-1RAs (e.g., liraglutide, semaglutide, and exendin-4) autophagy-specific markers, including beclin-1, LC3-II/LC3-I, ATG7, ATG3, and LAMP1, while normalising p62 levels.
    3 context sentences
    Summary · context
    This systematic review examined the effects of GLP-1RAs on autophagy in cell and animal models of AD and PD, as a proof of concept, to determine if these agents can be repurposed for the prevention and treatment of neurodegenerative and other mental disorders.
    Summary · context
    A systematic search on PubMed, Web of Science, and OVID (Medline, Embase, and APA PsycInfo databases) was conducted from inception to June 17, 2025.
    Summary · context
    The search yielded 142 studies, of which 14 were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.